Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer

Journal of the National Cancer Institute

Volumn 106, Issue 5, 2014, Pages

  Waldron, Levi ^a,b,c   Haibe Kains, Benjamin ^e,f   Culhane, Aedín C ^b,c   Riester, Markus ^b   Ding, Jie ^b   Wang, Xin Victoria ^b   Ahmadifar, Mahnaz ^b   Tyekucheva, Svitlana ^b   Bernau, Christoph ^b,g   Risch, Thomas ^b   Ganzfried, Benjamin Frederick ^b   Huttenhower, Curtis ^c   Birrer, Michael ^d   Parmigiani, Giovanni ^b,c  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; AGE; ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IMMUNE RESPONSE; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REPRODUCIBILITY; SYSTEMATIC REVIEW;

EID: 84902460506     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju049     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Cannistra SA, Bast RC Jr, Berek JS, et al. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol. 2003;21(10 Suppl):129s-132s.
3. Na YJ, Farley J, Zeh A, et al. Ovarian cancer: markers of response. Int J Gynecol Cancer. 2009;19(Suppl 2):S21-S29.
4. Chon HS, Lancaster JM. Microarray-based gene expression studies in ovarian cancer. Cancer Control. 2011;18(1):8-15.
5. Sabatier R, Finetti P, Cervera N, et al. Gene expression profiling and prediction of clinical outcome in ovarian cancer. Crit Rev Oncol Hematol. 2009;72(2):98-109.
6. Gomez-Raposo C, Mendiola M, Barriuso J, et al. Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol Oncol. 2010;118(1):88-92.
7. Farley J, Ozbun LL, Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res. 2008;18(5):538-548.
8. Alsheikh-Ali AA, Qureshi W, Al-Mallah MH, et al. Public availability of published research data in high-impact journals. PloS One. 2011;6(9):e24357.
9. Taminau J, Steenhoff D, Coletta A, et al. inSilicoDb: an R/Bioconductor package for accessing human Affymetrix expert-curated datasets from GEO. Bioinformatics. 2011;27(22):3204-3205.
10. Ioannidis J P, Allison DB, Ball CA, et al. Repeatability of published microar-ray gene expression analyses. Nat Genet. 2009;41(2):149-155.
11. Baggerly KA, Coombes KR. Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology. Ann Appl Stat. 2009;3(4):1309-1334
12. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
13. Denkert C, Budczies J, Darb-Esfahani S, et al. A prognostic gene expression index in ovarian cancer-validation across different independent data sets. J Pathol. 2009;218(2):273-280.
14. Bonome T, Levine DA, Shih J, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008;68(13):5478-5486.
15. Mok SC, Bonome T, Vathipadiekal V, et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfi-bril-associated glycoprotein 2. Cancer Cell. 2009;16(6):521-532.
16. Yoshihara K, Tsunoda T, Shigemizu D, et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res. 2012;18(5):1374-1585.
17. Yoshihara K, Tajima A, Yahata T, et al. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PloS One. 2010;5(3):e9615.
18. Bentink S, Haibe-Kains B, Risch T, et al. Angiogenic mRNA and micro-RNA gene expression signature predicts a novel subtype of serous ovarian cancer. PloS One. 2012;7(2):e30269.
19. Kang J, D'Andrea AD, Kozono D. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst. 2012;104(9):670-681.
20. Crijns A P, Fehrmann RS, de Jong S, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009;6(2):e24.
21. Kernagis DN, Hall AH, Datto MB. Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival. J Mol Diagnos. 2012;14(3):214-222.
22. Sabatier R, Finetti P, Bonensea J, et al. A seven-gene prognostic model for platinum-treated ovarian carcinomas. Br J Cancer. 2011;105(2):304-311.
23. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28(22):3555-3561.
24. Hernandez L, Hsu SC, Davidson B, et al. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 2010;70(10):4005-4014.
25. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198-5208.
26. Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2007;25(5):517-525.
27. Venet D, Dumont JE, Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comp Biol. 2011;7(10):e1002240.
28. Swisher EM, Taniguchi T, Karlan BY. Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time. J Natl Cancer Inst. 2012;104(9):642-645.
29. Ganzfried BF, Riester M, Haibe-Kains B, et al. curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database: The Journal of Biological Databases and Curation 2013;2013:bat013. doi:10.1093/database/bat013
30. Andrew B, Gina C, Janiel C, et al. Retraction: an integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2012;30(6):678.
31. Baggerly KA, Coombes KR, Neeley ES. Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer. J Clin Oncol. 2008;26(7):1186-1187.
32. Dressman HK, Potti A, Nevins JR, et al. In Reply. J Clin Oncol. 2008;26(7):1187-1188.
33. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006;8(1):118-127.
34. Fisher RA. Frequency distribution of the values of the correlation coefficient in samples from an indefinitely large population. Biometrika. 1915;10(4):507-521.
35. Uno H, Cai T, Pencina MJ, et al. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011;30(10):1105-1117.
36. Sneath PH, Sokal RR. Numerical Taxonomy. The Principles and Practice of Numerical Classification. San Francisco: H. Freeman and Co; 1973.
37. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
38. Zhao SD, Parmigiani G, Huttenhower C, et al. Más-o-menos: A simple sign averaging method for discrimnation in genomic data analysis. Harvard University Biostatistics Working Paper Series, 2013. http://biostats.bepress. com/harvardbiostat/paper158/. Accessed March 4, 2014.
39. Tukey J W. Tightening the clinical trial. Controlled Clinical Trials. 1993;14(4):266-285.
40. Leisch F. Sweave: dynamic generation of statistical reports using literate data analysis. In: Härdle W, Rönz B, eds. Compstat, 2002-Proceedings in Computational Statistics. Heidelberg, Germany: Physika Verlag; 2002:575-580.
41. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
42. Micheel CM, Nass SJ, Omenn GS. Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC: National Academies Press; 2012.
43. Witten DM, Tibshirani R. Scientific research in the age of omics: the good, the bad, and the sloppy. J Am Med Inform Assoc. 2013;20(1):125-127.
44. Kern SE. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. 2012;72(23):6097-6101.
45. Townsend NC, Ruth K, Al-Saleem T, et al. Gleason scoring at a comprehensive cancer center: what's the difference? J Natl Comp Cancer Net. 2013;11(7):812-819.
46. Lin Y, Chappell R, Gonen M. A systematic selection method for the development of cancer staging systems. [published online ahead of print May 22, 2013]. Stat Meth Med Res. 2013; doi:10.1177/0962280213486853.
47. Riester M, Wei W, Waldron L, et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1, 525 patient samples. J Natl Cancer Inst. 2014;XX(X):XXX-XXX.
48. Leek JT, Scharpf RB, Bravo HC, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet. 2010;11(10):733-739.